Opus Genetics, Inc. Common Stock

Opus Genetics announced successful FDA alignment on its Phase 3 clinical trial design for OPGx-LCA5, a gene therapy for LCA5-associated inherited retinal disease. The FDA indicated the company may submit a Biologics License Application based on 6-month efficacy data, with 12-month durability data provided during review. Phase 3 dosing is expected...

Opus Genetics announced a virtual R&D Science Forum scheduled for June 16, 2026, featuring leading ophthalmology experts to discuss the company's gene therapy pipeline for inherited retinal diseases. The forum will highlight three programs entering clinical testing targeting RDH12, MERTK, and RHO mutations, along with updates on ongoing LCA5 and ...

Opus Genetics, a clinical-stage biopharmaceutical company developing gene therapies for inherited retinal diseases, announced it will present at the 2026 Jefferies Global Healthcare Conference on June 3, 2026. The company is advancing seven AAV-based programs, with lead candidates OPGx-LCA5 and OPGx-BEST1 targeting different retinal disorders.

Opus Genetics, a clinical-stage biopharmaceutical company developing gene therapies for inherited retinal diseases, announced that management will present at the RBC Capital Markets 2026 Global Healthcare Conference on May 19, 2026. The company is advancing its pipeline of seven AAV-based programs, with lead candidates OPGx-LCA5 and OPGx-BEST1.

The presbyopia market is projected to grow at a CAGR of 4.9% from 2026-2036, driven by an aging global population and expanding treatment options. The market was valued at USD 11 billion in 2025 across seven major markets, with the US accounting for 50% of the market. Multiple emerging therapies and devices are expected to enter the market, inclu...